Regeneron expects $24M IPR&D charge in Q2 2024, ~$0.18 EPS hit

REGENERON PHARMACEUTICALS, INC.

2024-Q2 EPS reported $18.68 revenue$6,692,100,000

Estimated pre-tax acquired IPR&D charge of ~$24 million for Q2 2024.
Charge expected to negatively impact GAAP and non-GAAP EPS by ~$0.18 per diluted share.
Charge relates to up-front payments and equity premium on collaboration and licensing deals.
Results are preliminary and subject to financial close procedures; actual may vary.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.